180 related articles for article (PubMed ID: 32988624)
21. Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial.
Oza AM; Cibula D; Benzaquen AO; Poole C; Mathijssen RH; Sonke GS; Colombo N; Špaček J; Vuylsteke P; Hirte H; Mahner S; Plante M; Schmalfeldt B; Mackay H; Rowbottom J; Lowe ES; Dougherty B; Barrett JC; Friedlander M
Lancet Oncol; 2015 Jan; 16(1):87-97. PubMed ID: 25481791
[TBL] [Abstract][Full Text] [Related]
22. Olaparib monotherapy in patients with advanced relapsed ovarian cancer and a germline BRCA1/2 mutation: a multistudy analysis of response rates and safety.
Matulonis UA; Penson RT; Domchek SM; Kaufman B; Shapira-Frommer R; Audeh MW; Kaye S; Molife LR; Gelmon KA; Robertson JD; Mann H; Ho TW; Coleman RL
Ann Oncol; 2016 Jun; 27(6):1013-1019. PubMed ID: 26961146
[TBL] [Abstract][Full Text] [Related]
23. [Effect and Mechanism of Radiosensitization of Poly (ADP-Ribose) Polymerase Inhibitor n Lewis Cells and Xenografts].
Wang W; Duan B; Zeng L
Zhongguo Fei Ai Za Zhi; 2016 Jan; 19(1):16-23. PubMed ID: 26805733
[TBL] [Abstract][Full Text] [Related]
24. Poly (ADP) ribose polymerase inhibition: A potential treatment of malignant peripheral nerve sheath tumor.
Kivlin CM; Watson KL; Al Sannaa GA; Belousov R; Ingram DR; Huang KL; May CD; Bolshakov S; Landers SM; Kalam AA; Slopis JM; McCutcheon IE; Pollock RE; Lev D; Lazar AJ; Torres KE
Cancer Biol Ther; 2016; 17(2):129-38. PubMed ID: 26650448
[TBL] [Abstract][Full Text] [Related]
25. Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer.
Ray-Coquard I; Pautier P; Pignata S; Pérol D; González-Martín A; Berger R; Fujiwara K; Vergote I; Colombo N; Mäenpää J; Selle F; Sehouli J; Lorusso D; Guerra Alía EM; Reinthaller A; Nagao S; Lefeuvre-Plesse C; Canzler U; Scambia G; Lortholary A; Marmé F; Combe P; de Gregorio N; Rodrigues M; Buderath P; Dubot C; Burges A; You B; Pujade-Lauraine E; Harter P;
N Engl J Med; 2019 Dec; 381(25):2416-2428. PubMed ID: 31851799
[TBL] [Abstract][Full Text] [Related]
26. A Phase II study of olaparib in breast cancer patients: biological evaluation from a 'window of opportunity' trial.
Roviello G; Milani M; Gobbi A; Dester M; Cappelletti MR; Allevi G; Aguggini S; Ravelli A; Gussago F; Cocconi A; Zanotti L; Senti C; Strina C; Bottini A; Generali D
Future Oncol; 2016 Oct; 12(19):2189-93. PubMed ID: 27324108
[TBL] [Abstract][Full Text] [Related]
27. Tolerance and toxicity of the PARP inhibitor olaparib in older women with epithelial ovarian cancer.
Dockery LE; Tew WP; Ding K; Moore KN
Gynecol Oncol; 2017 Dec; 147(3):509-513. PubMed ID: 29037805
[TBL] [Abstract][Full Text] [Related]
28. Low levels of circulating estrogen sensitize PTEN-null endometrial tumors to PARP inhibition in vivo.
Janzen DM; Paik DY; Rosales MA; Yep B; Cheng D; Witte ON; Kayadibi H; Ryan CM; Jung ME; Faull K; Memarzadeh S
Mol Cancer Ther; 2013 Dec; 12(12):2917-28. PubMed ID: 24222661
[TBL] [Abstract][Full Text] [Related]
29. Combination of Olaparib with radiotherapy for triple-negative breast cancers: One-year toxicity report of the RADIOPARP Phase I trial.
Loap P; Loirat D; Berger F; Cao K; Ricci F; Jochem A; Raizonville L; Mosseri V; Fourquet A; Kirova Y
Int J Cancer; 2021 Nov; 149(10):1828-1832. PubMed ID: 34270809
[TBL] [Abstract][Full Text] [Related]
30. Olaparib maintenance monotherapy in platinum-sensitive, relapsed ovarian cancer without germline
Poveda AM; Davidson R; Blakeley C; Milner A
Future Oncol; 2019 Nov; 15(32):3651-3663. PubMed ID: 31553234
[TBL] [Abstract][Full Text] [Related]
31. Olaparib Desensitization in a Patient with Recurrent Peritoneal Cancer.
Grabowski JP; Sehouli J; Glajzer J; Worm M; Zuberbier T; Maurer M; Fluhr JW
N Engl J Med; 2018 Nov; 379(22):2176-2177. PubMed ID: 30485775
[No Abstract] [Full Text] [Related]
32. Anti-tumor activity of olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, in cultured endometrial carcinoma cells.
Miyasaka A; Oda K; Ikeda Y; Wada-Hiraike O; Kashiyama T; Enomoto A; Hosoya N; Koso T; Fukuda T; Inaba K; Sone K; Uehara Y; Kurikawa R; Nagasaka K; Matsumoto Y; Arimoto T; Nakagawa S; Kuramoto H; Miyagawa K; Yano T; Kawana K; Osuga Y; Fujii T
BMC Cancer; 2014 Mar; 14():179. PubMed ID: 24625059
[TBL] [Abstract][Full Text] [Related]
33. First phase 1 clinical study of olaparib in pediatric patients with refractory solid tumors.
Takagi M; Ogawa C; Iehara T; Aoki-Nogami Y; Ishibashi E; Imai M; Kimura T; Nagata M; Yasuhara M; Masutani M; Yoshimura K; Tomizawa D; Ogawa A; Yonemori K; Morishita A; Miyamoto S; Takita J; Kihara T; Nobori K; Hasebe K; Miya F; Ikeda S; Shioda Y; Matsumoto K; Fujimura J; Mizutani S; Morio T; Hosoi H; Koike R
Cancer; 2022 Aug; 128(15):2949-2957. PubMed ID: 35593736
[TBL] [Abstract][Full Text] [Related]
34. A phase I study of the PD-L1 inhibitor, durvalumab, in combination with a PARP inhibitor, olaparib, and a VEGFR1-3 inhibitor, cediranib, in recurrent women's cancers with biomarker analyses.
Zimmer AS; Nichols E; Cimino-Mathews A; Peer C; Cao L; Lee MJ; Kohn EC; Annunziata CM; Lipkowitz S; Trepel JB; Sharma R; Mikkilineni L; Gatti-Mays M; Figg WD; Houston ND; Lee JM
J Immunother Cancer; 2019 Jul; 7(1):197. PubMed ID: 31345267
[TBL] [Abstract][Full Text] [Related]
35. Maintenance olaparib in advanced ovarian cancer.
Burki TK
Lancet Oncol; 2018 Dec; 19(12):e671. PubMed ID: 30509885
[No Abstract] [Full Text] [Related]
36. A phase I dose-finding, pharmacokinetics and genotyping study of olaparib and lurbinectedin in patients with advanced solid tumors.
Poveda A; Oaknin A; Romero I; Guerrero-Zotano A; Fariñas-Madrid L; Rodriguez-Freixinos V; Mallol P; Lopez-Reig R; Lopez-Guerrero JA
Sci Rep; 2021 Feb; 11(1):4433. PubMed ID: 33627685
[TBL] [Abstract][Full Text] [Related]
37. Randomized, Double-Blind Phase II Trial With Prospective Classification by ATM Protein Level to Evaluate the Efficacy and Tolerability of Olaparib Plus Paclitaxel in Patients With Recurrent or Metastatic Gastric Cancer.
Bang YJ; Im SA; Lee KW; Cho JY; Song EK; Lee KH; Kim YH; Park JO; Chun HG; Zang DY; Fielding A; Rowbottom J; Hodgson D; O'Connor MJ; Yin X; Kim WH
J Clin Oncol; 2015 Nov; 33(33):3858-65. PubMed ID: 26282658
[TBL] [Abstract][Full Text] [Related]
38. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study.
Gelmon KA; Tischkowitz M; Mackay H; Swenerton K; Robidoux A; Tonkin K; Hirte H; Huntsman D; Clemons M; Gilks B; Yerushalmi R; Macpherson E; Carmichael J; Oza A
Lancet Oncol; 2011 Sep; 12(9):852-61. PubMed ID: 21862407
[TBL] [Abstract][Full Text] [Related]
39. Preclinical evaluation of olaparib and metformin combination in BRCA1 wildtype ovarian cancer.
Hijaz M; Chhina J; Mert I; Taylor M; Dar S; Al-Wahab Z; Ali-Fehmi R; Buekers T; Munkarah AR; Rattan R
Gynecol Oncol; 2016 Aug; 142(2):323-31. PubMed ID: 27282964
[TBL] [Abstract][Full Text] [Related]
40. Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.
Moore K; Colombo N; Scambia G; Kim BG; Oaknin A; Friedlander M; Lisyanskaya A; Floquet A; Leary A; Sonke GS; Gourley C; Banerjee S; Oza A; González-Martín A; Aghajanian C; Bradley W; Mathews C; Liu J; Lowe ES; Bloomfield R; DiSilvestro P
N Engl J Med; 2018 Dec; 379(26):2495-2505. PubMed ID: 30345884
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
